We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.075 | 0.26% | 28.895 | 28.95 | 28.67 | 28.88 | 21,775,909 | 19:48:11 |
From May 2019 to May 2024
By Colin Kellaher
Pfizer Inc. (PFE) on Wednesday said it has acquired a 15% stake in Vivet Therapeutics and will collaborate with the privately held gene-therapy company on the development of a potential breakthrough therapy for the chronic liver disorder Wilson disease.
The New York drug maker said the deal includes an option to buy the rest of Paris-based Vivet.
Pfizer said it paid about $51 million upon signing the deal, and said it could pay up $635.8 million, including the option-exercise payment and subject to certain clinical, regulatory and commercial milestones.
Pfizer said it will work with Vivet to develop VTX-801, Vivet's proprietary treatment for Wilson disease, a rare, chronic and potentially life-threatening liver disorder that causes serious copper poisoning.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 20, 2019 07:14 ET (11:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
